Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Puma Biotechnology
Puma Biotechnology Announces New Updates And Changes In Breast Cancer Treatment
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference | Business Wire
Puma Biotechnology, Inc. 2020 Current Report 8-K
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Why Puma Biotechnology Is Soaring Today | Nasdaq
Puma Biotechnology
Puma Biotechnology Inc. | BioWorld
Jobs with Puma Biotechnology
Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire